Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium + lactobacillus
- Development stage
- Phase 4
- Lead developer
- Creative Biolabs
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Intravaginal
01
Overview
A **combined probiotic product containing organisms from the genera Lactobacillus and Bifidobacterium**. In the provided sources, this name does not identify a single defined strain-level drug product, brand, or sponsor-specific asset; rather, it refers to a mixed probiotic preparation used in human studies, including a randomized placebo-controlled trial in children and adolescents with atopic dermatitis and a feasibility trial during cytotoxic chemotherapy for solid tumors. Its intended mechanism is **microbiome modulation**: oral administration of live commensal bacteria is intended to alter gut microbial composition and metabolic signaling, strengthen epithelial barrier and immune homeostasis, and indirectly modulate inflammatory and tolerogenic immune pathways. Because the exact species, strains, manufacturer, and formulation are not specified by the queried name, this should be treated as a **nonspecific probiotic combination descriptor** rather than a uniquely identifiable pharmaceutical asset.
- Brand names
- Culturelle Baby Digestive Calm and ComfortFlorajen3Florajen-3Florajen 3Nature's Bounty ProbioticPhillips Colon HealthPrimadophilus Bifidus
- Other names
- Bifidobacterium LactobacillusLactobacillus and Bifidobacteriumlactobacilli + bifidobacteriacombined probioticsmixture of probiotics
Beyond the preview
Go deeper on bifidobacterium + lactobacillus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium + lactobacillus.